Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers

Authors

Yao Zhang (ORCID: https://orcid.org/0000-0003-1174-7049)
Qiuxiang Ou (ORCID: https://orcid.org/0000-0002-2961-2057)
Zhihuang Hu
Bo Yu (ORCID: https://orcid.org/0000-0002-0347-0927)
Ying Lin (ORCID: https://orcid.org/0000-0002-4321-0695)
Hua Bao (ORCID: https://orcid.org/0000-0001-5774-8755)
Kainan Xiong (ORCID: https://orcid.org/0000-0003-4508-6920)
Song Wang (ORCID: https://orcid.org/0000-0002-5198-8173)
Jialei Wang (ORCID: https://orcid.org/0000-0001-9977-2219)
Si Sun
Xinmin Zhao
Huijie Wang (ORCID: https://orcid.org/0000-0002-1451-5158)
Cuicui Liu (ORCID: https://orcid.org/0000-0003-1592-9384)
Hui Yu (ORCID: https://orcid.org/0000-0003-3103-9672)
Xianghua Wu (ORCID: https://orcid.org/0000-0001-7348-0373)
Zhenhua Wu (ORCID: https://orcid.org/0009-0006-7109-7315)

Institutions

Shanghai Medical College of Fudan University (CN)
Fudan University Shanghai Cancer Center (CN)
Genesee Community College (US)

Publication Details

Journal: Translational Lung Cancer Research
Published: 2025-10-01
DOI: https://doi.org/10.21037/tlcr-2025-545
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers

Yao Zhang, Qiuxiang Ou, Zhihuang Hu, Bo Yu et al.

Oct 1, 2025

Translational Lung Cancer Research

Lung Cancer Treatments and Mutations

article

Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers

Yao Zhang, Qiuxiang Ou, Zhihuang Hu, Bo Yu, Ying Lin, Hua Bao, Kainan Xiong, Song Wang, Jialei Wang, Si Sun, Xinmin Zhao, Huijie Wang, Cuicui Liu, Hui Yu, Xianghua Wu, Zhenhua Wu

October 1, 2025article en

Abstract

No abstract available for this paper.

Translational Lung Cancer ResearchVol. 14(10)

Shanghai Medical College of Fudan University (CN), Fudan University Shanghai Cancer Center (CN), Genesee Community College (US)

Openalex Percentile: Top 55%

Lung Cancer Treatments and Mutations

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers — Yao Zhang, Qiuxiang Ou, et al. · Translational Lung Cancer Research (2025) | TGRS Research Map | TGRS